文献速递心血管技术与安全MR

心脏MRI钆对比剂:154779例欧洲患者中线性与大环螯合物的使用及安全性分析

Gadolinium-based Contrast Agents for Cardiac MRI: Use of Linear and Macrocyclic Agents with Associated Safety Profile from 154 779 European Patients.
PubMed 文献 · Radiol Cardiothorac Imaging · 2020-10-29

原文未述局限性

要点

  • 大环钆对比剂急性不良事件风险低于线性制剂(多变量OR 0.634)。
  • 总体急性不良事件率0.36%,以轻度和中度为主,重度仅0.03%。
  • 2018-2019年大环制剂使用几乎完全取代线性制剂。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To assess current use and acute safety profiles of gadolinium-based contrast agents (GBCAs) in cardiac MRI given recent suspensions of GBCA approval.

MATERIALS AND METHODS: Patients were retrospectively included from the multinational multicenter European Society of Cardiovascular Radiology (ESCR) MR/CT Registry collected between January 2013 and October 2019. GBCA-associated acute adverse events (AAEs) were classified as mild (self-limiting), moderate (pronounced AAE requiring medical management), and severe (life threatening). Multivariable generalized linear mixed-effect models were used to assess AAE likelihood.

RESULTS: A total of 154 779 patients (average age, 53 years ± 19 [standard deviation]; 99 106 men) who underwent cardiac MRI were included, the majority of whom underwent administration of GBCAs (94.2% [n = 145 855]). While linear GBCAs were used in 15.2% of examinations through 2011, their use decreased to less than 1% in 2018 and 2019. Overall, 0.36% (n = 556) of AAEs were documented (mild, 0.12% [n = 178]; moderate, 0.21% [n = 331]; severe, 0.03% [n = 47]). For nonenhanced cardiac MRI, examination-related events were reported in 2.59% (231 of 8924) of cases, the majority of which were anxiety (0.98% [n = 87]) and dyspnea (0.93% [n = 83]). AAE rates varied significantly by pharmacologic stressor, GBCA molecular structure (macrocyclic vs linear GBCA: multivariable odds ratio, 0.634; 95% confidence interval: 0.452, 0.888; P = .008), GBCA subtype, and imaging indication.

CONCLUSION: Gadolinium-based contrast agent administration changed according to recent regulatory decisions, with use of macrocyclic agents almost exclusively in 2018 and 2019; these agents also demonstrated a favorable acute safety profile.Supplemental material is available for this article.© RSNA, 2020.

来源:Radiol Cardiothorac Imaging,查看原文。版权归原作者所有。

引用

  1. Uhlig J, Al-Bourini O, Salgado R, et al. Gadolinium-based Contrast Agents for Cardiac MRI: Use of Linear and Macrocyclic Agents with Associated Safety Profile from 154 779 European Patients. Radiol Cardiothorac Imaging. 2020. PMID: 33778622. doi:10.1148/ryct.2020200102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。